Brompheniramine / Codeine / Phenylephrine Dosage
Medically reviewed on January 15, 2018.
Applies to the following strengths: 1.33 mg-6.33 mg-3.33 mg/5 mL; 4 mg-10 mg-7.5 mg/5 mL; 4 mg-10 mg-10 mg/5 mL
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Cough and Nasal Congestion
Brompheniramine/codeine/phenylephrine 4 mg-10 mg-10 mg/5 mL oral liquid:
5 mL orally every 4 to 6 hours not to exceed 30 mL daily
Brompheniramine/codeine/phenylephrine 1.33 mg-6.33 mg-3.33 mg/5 mL oral liquid:
15 mL orally every 4 to 6 hours not to exceed 90 mL daily
-Liquid preparations should be measured with an accurate milliliter measuring device.
Uses: Temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold.
Renal Dose Adjustments
Use with caution
Liver Dose Adjustments
Use with caution
Elderly: Use with caution generally starting at the lower end of the dosing range
The US FDA recommends against use of codeine-containing cough and cold medications in patients less than 18 years because it has been determined that the risks outweigh benefits.
Consult WARNINGS section for additional precautions.
US Controlled Substance: Schedule V
Data not available
-Take orally with or without food
-Oral measuring devices should be used to ensure accuracy in dosing; a household teaspoon should not be considered an accurate measuring device
-Protect from moisture and light
-Patients who are ultra-rapid metabolizers of codeine due to a CYP450 2D6 polymorphism, will convert codeine more rapidly and completely to morphine resulting in unexpectedly high morphine levels, which may be life-threatening.
-Codeine use is contraindicated in the postoperative period in pediatric patients who have undergone tonsillectomy and/or adenoidectomy.
-Cardiovascular: Monitor for signs of hypotension, especially in those whose blood pressure is compromised
-Respiratory: Monitor for respiratory depression
-Gastrointestinal: Monitor for constipation and decreased bowel motility
-Patients should be monitored for the development of addiction, abuse, or misuse.
-Patients should understand that codeine use can result in addiction, abuse, and misuse.
-Patients should understand risks of life-threatening respiratory depression and when this risk is greatest; patients should be aware that a genetic mutation may result in greater codeine toxicity in some patients; breastfed infants of women who have this genetic mutation are also at risk.
-Women who are breastfeeding, pregnant, or planning to become pregnant should speak to their healthcare provider before using this product.
-This drug may cause drowsiness, dizziness, or impair thinking or motor skills; patients should avoid driving or operating machinery while taking this drug
-Concomitant use of alcohol, sedatives, and tranquilizers may increase drowsiness; patients should avoid alcohol and consult with their healthcare provider regarding concomitant use of other CNS depressants.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about brompheniramine/codeine/phenylephrine
- Brompheniramine/codeine/phenylephrine Side Effects
- During Pregnancy
- Drug Interactions
- En Español
- 1 Review
- Drug class: upper respiratory combinations